Loxapine
As of the edition of 20 October 2026, Loxapine is a small molecule: marketed, first approved in 1978 (FR); acts on DRD2, DRD3 and DRD4 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2013
- Kind
- Small molecule
- Brand name
- Loxitane
- First approved
- 8 August 1978 (FR)
- Approvals on record
- 12 in 3 regions
- Holder of the most recent approval
- Ferrer Internacional; 5 holders in all
- Registered trials
- 23, 2 stopped early
- Disease areas
- Nervous system; Mental health; Lungs and airways; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product4 company-target rows are on route B because of Loxapine.
See the 4 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 3 | 0 | 0 |
| Phase 1 | 9 | 9 | 0 | 0 |
| Phase 2 | 4 | 3 | 0 | 1 |
| Phase 3 | 3 | 2 | 0 | 0 |
| Phase 4 | 3 | 2 | 0 | 1 |
| All trials | 23 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Nova Pneuma | Acquired holder and Lead sponsor of trials | 2009 to now |
| Ferrer Internacional | Applicant | 2013 to now |
| Teva | Acquired holder and Lead sponsor of trials | 2014 to now |
| Actavis Laboratories Ut | Acquired holder | 2015 to now |
| Pfizer | Earlier holder |